RXI Pharma (RXII) Reports Q4 Loss of $0.60/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq climbs to record after softer jobs data cools rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights
March 30, 2017 7:02 AM EDTMARLBOROUGH, Mass., March 30, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, today reported its financial results for the fourth quarter and year ended December 31, 2016, and provided a business update.
"We believe RXi is well positioned for a strong business and development performance in 2017 due to the acquisition of MirImmune Inc. and the strengthening of our balance sheet through a financing at the end of 2016.  As a result, the Company has already initiated programs in the immuno-oncology and... More
